Immune Design (IMDZ) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Immune Design (IMDZ) Misses Q2 EPS by 7c
August 12, 2015 4:01 PM EDT
SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the announcement of three new immuno-oncology clinical collaborations and a cash position of $129.0 million, inclusive of net proceeds from a public offering in April 2015.
Corporate Update and Recent Highlights
On August 10, 2015, Immune Design announced it had entered into two clinical trial collaborations with Merck (NYSE:
MRK) to evaluate two immuno-oncology...
More
August 12, 2015 4:01 PM EDT
SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the announcement of three new immuno-oncology clinical collaborations and a cash position of $129.0 million, inclusive of net proceeds from a public offering in April 2015.
Corporate Update and Recent Highlights
On August 10, 2015, Immune Design announced it had entered into two clinical trial collaborations with Merck (NYSE:
MRK) to evaluate two immuno-oncology...
More
